A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy
The purpose of this study is to evaluate the efficacy, safety and tolerability of palifermin on the incidence of oral mucositis in subjects with locally advanced head and neck cancer receiving postoperative radiotherapy.
Head and Neck Cancer
DRUG: Placebo|DRUG: palifermin
Incidence of treatment-emergent proteinuria, 11 weeks|Duration of treatment-emergent proteinuria, 11 weeks|Incidence of chronic proteinuria, 11 weeks|Time (days) to onset of treatment-emergent proteinuria, 11 weeks|Maximum protein-to-creatinine ratio values during the treatment period, 11 weeks|Pharmacokinetic profile to include Systemic clearance, volume of distribution at steady state, estimated initial concentration, area under the conc-time curve, terminal half-life and mean residual time, in Week 1
Time (days) to onset of severe Oral Mucositis WHO grade 3 or 4, 11 weeks|Disease status at End of Treatment visit, 11 weeks|Incidence of serum anti-palifermin antibody formation, 11 weeks|Incidence of second primary tumors, up to 10 years (Long-Term Follow-Up phase)|Incidence of other malignancies, up to 10 years (Long-Term Follow-Up phase)|Progression-free survival, up to 10 years (Long-Term Follow-Up phase)|Overall survival, up to 10 years (Long-Term Follow-Up phase)|Incidence of adverse events and laboratory abnormalities, 11 weeks|Incidence (%) and duration (days) of severe Oral Mucositis WHO grade 3 or 4, 11 weeks
The purpose of this study is to evaluate the efficacy, safety and tolerability of palifermin on the incidence of oral mucositis in subjects with locally advanced head and neck cancer receiving postoperative radiotherapy.